LT3091029T - Anti-il13 antikūno kompozicijos - Google Patents

Anti-il13 antikūno kompozicijos

Info

Publication number
LT3091029T
LT3091029T LTEP16169916.0T LT16169916T LT3091029T LT 3091029 T LT3091029 T LT 3091029T LT 16169916 T LT16169916 T LT 16169916T LT 3091029 T LT3091029 T LT 3091029T
Authority
LT
Lithuania
Prior art keywords
antibody compositions
antibody
compositions
Prior art date
Application number
LTEP16169916.0T
Other languages
English (en)
Inventor
Ajay Deshmukh
Joumana ZEID
Thomas M. SCHERER
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of LT3091029T publication Critical patent/LT3091029T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
LTEP16169916.0T 2011-10-31 2012-10-30 Anti-il13 antikūno kompozicijos LT3091029T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161553916P 2011-10-31 2011-10-31

Publications (1)

Publication Number Publication Date
LT3091029T true LT3091029T (lt) 2023-02-27

Family

ID=48192677

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16169916.0T LT3091029T (lt) 2011-10-31 2012-10-30 Anti-il13 antikūno kompozicijos

Country Status (27)

Country Link
US (4) US10000562B2 (lt)
EP (3) EP4218937A3 (lt)
JP (4) JP6120452B2 (lt)
KR (4) KR101994809B1 (lt)
CN (5) CN109078182B (lt)
AR (2) AR088579A1 (lt)
AU (3) AU2012332767C1 (lt)
BR (1) BR112014008864B1 (lt)
CA (2) CA2849210C (lt)
DK (1) DK3091029T5 (lt)
ES (1) ES2936387T3 (lt)
FI (1) FI3091029T3 (lt)
HK (1) HK1201857A1 (lt)
HR (1) HRP20230153T1 (lt)
HU (1) HUE061728T2 (lt)
IL (2) IL232053B (lt)
LT (1) LT3091029T (lt)
MX (2) MX363226B (lt)
MY (2) MY197851A (lt)
PL (1) PL3091029T3 (lt)
PT (1) PT3091029T (lt)
RS (1) RS63948B1 (lt)
RU (1) RU2665810C2 (lt)
SG (1) SG11201401903PA (lt)
SI (1) SI3091029T1 (lt)
WO (1) WO2013066866A1 (lt)
ZA (2) ZA201401779B (lt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
CA3101119C (en) 2011-06-24 2023-07-04 Kci Licensing, Inc. Reduced-pressure dressings employing tissue-fixation elements
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
HRP20230065T1 (hr) 2011-10-28 2023-03-03 Prothena Biosciences Limited Humanizirana protutijela koja prepoznaju alfa-sinuklein
AR088579A1 (es) 2011-10-31 2014-06-18 Genentech Inc Formulaciones de anticuerpos
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
SG11201404321YA (en) 2012-01-27 2014-08-28 Neotope Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3683232A1 (en) * 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
JPWO2015079977A1 (ja) * 2013-11-26 2017-03-16 シャープ株式会社 抗体分離方法、抗体評価方法、医薬の評価方法、及び、抗体の２次元電気泳動用キット
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
RU2694820C9 (ru) 2014-12-23 2019-08-12 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
ES3062420T3 (en) * 2016-08-25 2026-04-10 California Inst Of Techn Ascaroside treatment of eosinophilic esophagitis
HUE063135T2 (hu) 2016-09-23 2023-12-28 Hoffmann La Roche IL-13 antagonisták alkalmazásai atópiás dermatitis kezelésére
CN110167531B (zh) * 2017-01-11 2025-06-03 赛特瑞恩股份有限公司 稳定的液体调配物
JP2019048091A (ja) * 2018-10-23 2019-03-28 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
KR102578103B1 (ko) * 2019-01-02 2023-09-18 도소 가부시키가이샤 광 산란 검출기 및 광 산란 검출기를 위한 방법
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
KR20220122993A (ko) * 2019-11-26 2022-09-05 코메라 라이프 사이언시스, 인코포레이티드 바이오폴리머 제형을 위한 부형제 화합물
KR20230093293A (ko) * 2020-10-22 2023-06-27 알라코스 인크. 항-siglec-8 항체 제형
TWI847170B (zh) 2021-07-16 2024-07-01 美商德米拉股份有限公司 用於治療異位性皮炎之il-13抗體
TWI859566B (zh) 2021-08-13 2024-10-21 美商德米拉股份有限公司 用於治療異位性皮膚炎之il-13抗體
JP2024535831A (ja) * 2021-09-15 2024-10-02 デルミラ・インコーポレイテッド 結節性痒疹の治療のためのｉｌ－１３阻害剤
EP4519315A1 (en) 2022-05-05 2025-03-12 Dermira, Inc. Il-13 antibodies for the treatment of atopic dermatitis
MA68845A1 (fr) 2022-06-17 2025-11-28 Apogee Therapeutics, Inc. Anticorps se liant à l'interleukine 13 et méthodes d'utilisation
JP2026507718A (ja) 2023-03-08 2026-03-04 デルミラ・インコーポレイテッド アトピー性皮膚炎の治療のためのｉｌ－１３抗体
AU2024356800A1 (en) 2023-10-05 2026-04-02 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
TW202544035A (zh) 2023-12-14 2025-11-16 美商德米拉股份有限公司 用於治療全年性過敏性鼻炎之il-13抗體
WO2025128984A1 (en) 2023-12-14 2025-06-19 Dermira, Inc. Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
AR134791A1 (es) * 2023-12-20 2026-04-01 Apogee Therapeutics Inc Composiciones farmacéuticas de anticuerpos que se unen a interleucina 13
WO2025137523A2 (en) * 2023-12-20 2025-06-26 Apogee Therapeutics, Inc. Pharmaceutical formulations of antibodies that bind interleukin 13
WO2025155802A1 (en) * 2024-01-19 2025-07-24 Allakos Inc. Anti-siglec-6 antibody formulations
TW202600591A (zh) 2024-03-01 2026-01-01 美商德米拉股份有限公司 用於治療發炎後皮膚色素過多或色素過少之ｉｌ—１３抗體
WO2026076260A1 (en) 2024-10-03 2026-04-09 Ashibio, Inc. Methods and compositions for mmp-9 inhibition for use with non-genetic heterotopic ossification disorders

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
DK0674506T3 (da) 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
DE69519382T3 (de) 1994-09-09 2008-09-18 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996040072A2 (en) 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
JP4533626B2 (ja) * 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
BRPI0407649A (pt) 2003-02-28 2006-02-21 Ares Trading Sa formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
JP4943161B2 (ja) * 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL1942939T5 (pl) 2005-09-30 2021-10-11 Medimmune Limited Kompozycja przeciwciała interleukiny-13
US7910708B2 (en) * 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
JP5405122B2 (ja) * 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
WO2008086395A2 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
UA102120C2 (ru) * 2008-12-03 2013-06-10 Астеллас Дойчленд Гмбх Пероральная форма дозирования бендамустина
BRPI1006519A2 (pt) * 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
CA2792125C (en) * 2010-03-22 2019-02-12 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
CN102958538A (zh) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AR088579A1 (es) * 2011-10-31 2014-06-18 Genentech Inc Formulaciones de anticuerpos

Also Published As

Publication number Publication date
IL276234B (en) 2022-04-01
WO2013066866A1 (en) 2013-05-10
JP6272950B2 (ja) 2018-01-31
CN121910869A (zh) 2026-04-24
CN109078182B (zh) 2022-08-12
EP3091029A1 (en) 2016-11-09
JP2019203002A (ja) 2019-11-28
US20260055178A1 (en) 2026-02-26
KR20190077127A (ko) 2019-07-02
JP2018048166A (ja) 2018-03-29
PL3091029T3 (pl) 2023-04-11
SI3091029T1 (sl) 2023-03-31
KR101994809B1 (ko) 2019-07-01
FI3091029T3 (fi) 2023-03-20
EP4218937A2 (en) 2023-08-02
MX2019002979A (es) 2020-02-10
CN104039826A (zh) 2014-09-10
KR20140084078A (ko) 2014-07-04
KR20170096212A (ko) 2017-08-23
US20140348855A1 (en) 2014-11-27
EP2773662A4 (en) 2015-07-01
US20190002552A1 (en) 2019-01-03
SG11201401903PA (en) 2014-05-29
AR124140A2 (es) 2023-02-15
AU2018232943A1 (en) 2018-10-11
BR112014008864B1 (pt) 2021-11-09
AU2016210757A1 (en) 2016-08-25
HUE061728T2 (hu) 2023-08-28
IL232053B (en) 2020-08-31
EP2773662A1 (en) 2014-09-10
MY187874A (en) 2021-10-26
KR20200065104A (ko) 2020-06-08
CA2849210C (en) 2020-07-14
MX363226B (es) 2019-03-15
AU2018232943B2 (en) 2020-07-23
AU2012332767A1 (en) 2014-04-10
MY197851A (en) 2023-07-20
RU2014116070A (ru) 2015-12-10
BR112014008864A2 (pt) 2018-08-07
US10947307B2 (en) 2021-03-16
AU2012332767B2 (en) 2016-05-12
EP3091029B1 (en) 2022-12-28
AR088579A1 (es) 2014-06-18
ES2936387T3 (es) 2023-03-16
CA3078979C (en) 2022-10-11
DK3091029T3 (da) 2023-01-30
US12492247B2 (en) 2025-12-09
EP4218937A3 (en) 2023-10-25
CA2849210A1 (en) 2013-05-10
DK3091029T5 (da) 2024-10-14
JP6921148B2 (ja) 2021-08-18
RU2665810C2 (ru) 2018-09-04
KR102259829B1 (ko) 2021-06-03
PT3091029T (pt) 2023-02-03
RS63948B1 (sr) 2023-02-28
CN116077644A (zh) 2023-05-09
CN109078182A (zh) 2018-12-25
JP2016193922A (ja) 2016-11-17
CN108704132A (zh) 2018-10-26
ZA201901490B (en) 2021-06-30
HRP20230153T1 (hr) 2023-03-31
CA3078979A1 (en) 2013-05-10
MX2014004992A (es) 2014-08-27
ZA201401779B (en) 2019-07-31
US10000562B2 (en) 2018-06-19
IL232053A0 (en) 2014-05-28
HK1201857A1 (en) 2015-09-11
US20210155684A1 (en) 2021-05-27
JP2014532664A (ja) 2014-12-08
IL276234A (en) 2020-09-30
NZ622654A (en) 2017-01-27
JP6120452B2 (ja) 2017-04-26
AU2012332767C1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
IL232053A0 (en) Antibody formulations
LT2791160T (lt) Modifikuotos mrnr sudėtys
LT2742151T (lt) Polimerazės kompozicija
BR112013022112A2 (pt) composição
DK2686017T3 (da) Oftalmisk sammensætning
BR112014004395A2 (pt) composição
BR112014003052A2 (pt) composições farmacêuticas
BR112013017183A2 (pt) composições de bepostatina
DK2694038T3 (da) Farmaceutisk sammensætning
CO6970594A2 (es) Composiciones hemostáticas
PT2720563T (pt) Resumo
EP2729131A4 (en) TOPICAL COMPOSITIONS
DK3513803T3 (da) Hæmostatiske sammensætninger
PT2543357T (pt) Resumo
CO6930367A2 (es) Composiciones farmaceúticas
CO6930368A2 (es) Composiciones de yodo-povidona estable
CO6862152A2 (es) Composición limpiadora
BR112013033808A2 (pt) composição
HUE037126T2 (hu) Immunogén készítmény
HUE040370T2 (hu) Gyógyszerkészítmények
EP2786976A4 (en) MONOLITHIC COMPOSITION
BR112014000015A2 (pt) formulação
FI11374U1 (fi) Bensiinikoostumukset
EP2730619A4 (en) COMPOSITION
PT2661870T (pt) Resumo